REPLIMUNE GROUP INC (REPL:NASDAQ)
$13.42 0.38 (2.9141%)
Analysed REPLIMUNE GROUP INC (REPL:NASDAQ) News Sources
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
07-08-2026
yahoo.com
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
08-08-2026
stocktwits.com
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
10-08-2026
stocktwits.com
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment
13-08-2026
yahoo.com
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
14-08-2026
yahoo.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19-08-2026
yahoo.com
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
27-08-2026
stocktwits.com
Replimune to Present at the Cantor Global Healthcare Conference 2026
03-09-2026
yahoo.com
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
01-10-2026
yahoo.com
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
09-10-2026
yahoo.com
What is the current price of REPLIMUNE GROUP INC (REPL:NASDAQ)?
The current price of REPLIMUNE GROUP INC (REPL:NASDAQ) is $13.42.
REPLIMUNE GROUP INC (REPL:NASDAQ) absolute price change since previous trading day?
The absolute price change of REPLIMUNE GROUP INC (REPL:NASDAQ) since the previous trading day is $0.38.
REPLIMUNE GROUP INC (REPL:NASDAQ) percentage price change since previous trading day?
The percentage price change of REPLIMUNE GROUP INC (REPL:NASDAQ) since the previous trading day is 2.9141%.
What is the most recent average sentiment score for REPLIMUNE GROUP INC (REPL:NASDAQ)?
The most recent average sentiment score for REPLIMUNE GROUP INC (REPL:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for REPLIMUNE GROUP INC (REPL:NASDAQ)?
The most recent sentiment for REPLIMUNE GROUP INC (REPL:NASDAQ) is .
SEC-8K** Filing Available For REPLIMUNE GROUP INC (REPL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.